Fagopyrum dibotyo nutraceuticals and methods of their use are provided. The disclosed F. dibotyo nutraceuticals are useful to improve or increase liver function and to treat liver diseases, especially those caused by viral hepatitis. In some embodiments, the F. dibotyo nutraceuticals also contain supplementary botanical extracts to confer additional health benefits.

Fagopyrum dibotyo nutraceuticals and methods of their use are provided. The disclosed F. dibotyo nutraceuticals are useful to improve or increase liver function and to treat liver diseases, especially those caused by viral hepatitis. In some embodiments, the F. dibotyo nutraceuticals also contain supplementary botanical extracts to confer additional health benefits.

The present invention relates to solid oral compositions with controlled release of active ingredients, comprising a core consisting of a monolithic matrix comprising at least one low-, medium- or high-viscosity hydroxypropyl methylcellulose, or a mixture thereof, a hydroxypropyl cellulose (HPC) and one or more superdisintegrant polymers, and an outer coating of said core consisting of a layer comprising hydroxypropyl methylcellulose and/or ethylcellulose, or of a gastroresistant layer or of a layer comprising ethylcellulose coated in turn with gastroresistant polymers.

The present invention relates to solid oral compositions with controlled release of active ingredients, comprising a core consisting of a monolithic matrix comprising at least one low-, medium- or high-viscosity hydroxypropyl methylcellulose, or a mixture thereof, a hydroxypropyl cellulose (HPC) and one or more superdisintegrant polymers, and an outer coating of said core consisting of a layer comprising hydroxypropyl methylcellulose and/or ethylcellulose, or of a gastroresistant layer or of a layer comprising ethylcellulose coated in turn with gastroresistant polymers.

A composition for the treatment of UTIs comprising: One of, a monosaccharide L-arabinose, L-frucose, D-mannose, L-rhamnose, L-xylose, lyxose or galactose; Extract from one of Boswellia serrata, Boswellia sacra or Boswellia carteri containing boswellic acids, terpenes and incensole acetate; Extract from the seeds of one of, Cucurbitaceae maxima, Cucurbitaceae pepo or Cucurbitaceae moschata; Turmeric extract; Green tea extract containing polyphenolic catechins; and, Piper nigrum.

A composition for the treatment of UTIs comprising: One of, a monosaccharide L-arabinose, L-frucose, D-mannose, L-rhamnose, L-xylose, lyxose or galactose; Extract from one of Boswellia serrata, Boswellia sacra or Boswellia carteri containing boswellic acids, terpenes and incensole acetate; Extract from the seeds of one of, Cucurbitaceae maxima, Cucurbitaceae pepo or Cucurbitaceae moschata; Turmeric extract; Green tea extract containing polyphenolic catechins; and, Piper nigrum.

A composition for the treatment of UTIs comprising: One of, a monosaccharide L-arabinose, L-frucose, D-mannose, L-rhamnose, L-xylose, lyxose or galactose; Extract from one of Boswellia serrata, Boswellia sacra or Boswellia carteri containing boswellic acids, terpenes and incensole acetate; Extract from the seeds of one of, Cucurbitaceae maxima, Cucurbitaceae pepo or Cucurbitaceae moschata; Turmeric extract; Green tea extract containing polyphenolic catechins; and, Piper nigrum.

The present invention provides a method of treating or delaying the onset of Alzheimer's disease or other neurological diseases in a patient having or at risk of developing Alzheimer's disease or other neurological diseases comprising administering to the subject an effective amount of an anti-angiogenic agent. In particular, the present invention provides a method of treating and/or delaying the onset of Alzheimer's disease or other neurological diseases by inhibiting Angiopoietin-2 mediated Tie-2 angiogenic pathway comprising administering to the subject an effective amount of an inhibitor of the Angiopoietin-2 mediated Tie-2 angiogenic pathway.

The present invention provides a method of treating or delaying the onset of Alzheimer's disease or other neurological diseases in a patient having or at risk of developing Alzheimer's disease or other neurological diseases comprising administering to the subject an effective amount of an anti-angiogenic agent. In particular, the present invention provides a method of treating and/or delaying the onset of Alzheimer's disease or other neurological diseases by inhibiting Angiopoietin-2 mediated Tie-2 angiogenic pathway comprising administering to the subject an effective amount of an inhibitor of the Angiopoietin-2 mediated Tie-2 angiogenic pathway.

The present disclosure provides a composition that may find utility in management of COVID-19. The inventors of the present disclosure surprisingly observed that ingredients of the composition of the present disclosure exhibit functional synergy therebetween, wherein the composition prevents virus replication and/or Virus entry into human cells, either wholly or in part, while modulating immune response of the patient. Hence, the composition of the present disclosure holds potential for wide spread usage in management of COVID-19, either alone or in combination with other preventive or palliative/symptomatic or therapeutic strategies.